Top

Supportive Care in Cancer

Published in:

01-02-2010 | Original Article

Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting

Authors: Mateya Trinkaus, Christine Simmons, Jeff Myers, George Dranatisaris, Mark Clemons

Published in: Supportive Care in Cancer | Issue 2/2010

Abstract

Background

Clinical trials exploring bisphosphonate (BP) use in patients with bone metastases from breast cancer (BC) consistently state skeletal-related event (SRE) rates >50%. These trials predominantly include patients with bone only disease, and also frequently use screening radiology to detect asymptomatic fractures. Both these variables are likely to increase the incidence of SREs and thereby overestimate BP benefit. Little data exists regarding the natural history of SREs among patients treated with i.v. BPs in the nontrial setting.

Materials and methods

Charts from two institutions (PMH and CVH) were reviewed to determine predictive risk factors for SRE development post i.v. pamidronate therapy in BC patients with bone metastases.

Results

Eighty-seven charts from 1999 to 2005 with complete outcome data were identified and reviewed. Pain was the most common presentation for bone metastases occurring in 49 women (56%). At diagnosis, 31 patients (35%) had bone only disease, and 57 (65%) had concomitant visceral metastases. Twenty-nine patients (33%) experienced an SRE prior to commencing BP treatment. Thirty-three women (38%) subsequently developed an SRE after a median of 5 BP treatments. SREs included radiation (79%), pathologic fractures (12%), and hypercalcemia (9%). On Cox regression, baseline history of osteoporosis (HR = 2.8; p = 0.045) and the presence of bone only disease (HR 3.0; p = 0.003) were predictive of SRE development. In patients with and without osteoporosis, median time to SRE was 305 and 866 days, respectively (p < 0.001).

Conclusion

The frequency of SREs in this study was significantly lower than that reported in clinical trials of i.v. BP use. The lower incidence of SREs in this setting could affect sample size calculations for future event-driven BP trials. While the greatest risk of SREs despite BP therapy appears to be in patients with osteoporosis and with metastatic disease confined to the skeleton, further prospective study is merited to confirm and characterize the impact of these risk factors on SRE development.

Coleman RE (2008) Risks and benefits of bisphosphonates. Br J Cancer 98:1736–1740. doi:10.1038/sj.bjc.6604382 CrossRefPubMed

Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55(1):61–66PubMed

Hillner BE, Ingle JN, Chlebowski RT et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042–4057. doi:10.1200/JCO.2003.08.017 CrossRefPubMed

Warr D, Johnston M (2004) Use of bisphosphonates in women with breast cancer. Practice guideline report no. 1-11. Hamilton ON: Cancer Care Ontario, Program in Evidence-Based Care; 2004. [Available online at: www.cancercare.on.ca/pdf/pebc1-11f.pdf; cited June 15 2008]

Petrut B, Trinkaus M, Simmons C et al (2008) A primer of bone metastases management in breast cancer. Curr Oncol 15(S1):S50–S57. doi:10.3747/co.2008.176 CrossRefPubMed

Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev CD003474.

Hortobagyi GN, Theriault RL, Lipton A et al (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate, Protocol 19, Aredia Breast Cancer Study Group. J Clin Oncol 16(6):2038–2044PubMed

Theriault RL, Lipton A, Hortobagyi GN et al (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17:846–854PubMed

Plunkett RA, Smith P, Rubens RD (2000) Risk of complications from bone metastases in breast cancer: implications for management. Eur J Cancer 36:476–482. doi:10.1016/S0959-8049(99)00331-7 CrossRefPubMed

10.

Clemons MJ, Dranitsaris G, Cole D et al (2006) Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer. Oncologist 11(3):227–233. doi:10.1634/theoncologist.11-3-227 CrossRefPubMed

11.

Gainford C, Dranitsaris G, Clemons M (2005) Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ 330(7494):769–773. doi:10.1136/bmj.330.7494.769 CrossRefPubMed

12.

Gnant M, Mlineritsch B, Schippinger W, et al (2008) Adjuvant ovarian suppression combined with tamoxifen or anastrazole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. Plenary Presentation. ASCO Annual Meeting May 30–June 3

13.

Verma S, Kerr-Cresswell D, Dranitsaris G et al (2004) Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian medical oncologists. Support Care Cancer 12:852–858. doi:10.1007/s00520-004-0671-9 CrossRefPubMed

14.

Clemons M, Enright K, Cesta A et al (2004) Do physicians follow systemic treatment and funding policy guidelines? Can J Clin Pharmacol 11:e168–e178PubMed

15.

Major P, Cook RJ (2008) Natural History of Skeletal Complications in Patients Receiving Chemotherapy for Breast Cancer Metastatic to Bone. Poster Presentation: SABC December 12–14 2008.

16.

Brufsky A (2008) Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist 13:187–195. doi:10.1634/theoncologist.2007-0152 CrossRefPubMed

17.

Friedlaender GE, Tross RB, Doganis AC et al (1984) Effects of chemotherapeutic agents on bone. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rate model. J Bone Joint Surg Am 66:602–607PubMed

18.

Chen Z, Maricic M, Pettinger M et al (2005) Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. Results from a Subgroup in the Women’s Health Initiative Observational Study. Cancer 104(7):1520–1530. doi:10.1002/cncr.21335 CrossRefPubMed

19.

Siris ES, Chen Y-T, Abbott TA et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108–1112. doi:10.1001/archinte.164.10.1108 CrossRefPubMed

20.

Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer 88(5):1082–1090. doi:10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z CrossRefPubMed

21.

Liauw W, Segelov E, Anna L et al (2005) Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer. BMC Cancer 5:89. doi:10.1186/1471-2407-5-89 CrossRefPubMed

22.

LoRusso P (2001) Analysis of skeletal related events in breast cancer and response to therapy. Semin Oncol 28(suppl 11):22–27. doi:10.1016/S0093-7754(01)90228-3 CrossRefPubMed

Title: Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting
Authors: Mateya Trinkaus
Christine Simmons
Jeff Myers
George Dranatisaris
Mark Clemons
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 2/2010
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-009-0645-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2010

The life-sustaining treatments among cancer patients at end of life and the caregiver’s experience and perspectives

The cancer anorexia-cachexia syndrome: myth or reality?

Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA

Marine phospholipids—a promising new dietary approach to tumor-associated weight loss

Construction of a new, objective prognostic score for terminally ill cancer patients: a multicenter study

Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double-blind, placebo-controlled study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer